BPMC Quote, Financials, Valuation and Earnings

Ardelyx has a net margin of 0.33% compared to Blueprint Medicines's net margin of -55.52%. Blueprint Medicines's return on equity of -49.13% beat Ardelyx's return on equity of -34.68%.

Blueprint Medicines has a consensus price target of $126.87, signalling downside risk potential of -1.19%. On the other hand Ardelyx has an analysts' consensus of $10.73 which suggests that it could grow by 195.52%. Given that Ardelyx has higher upside potential than Blueprint Medicines, analysts believe Ardelyx is more attractive than Blueprint Medicines.

Blueprint Medicines has a beta of 0.841, which suggesting that the stock is 15.895% less volatile than S&P 500. In comparison Ardelyx has a beta of 0.593, suggesting its less volatile than the S&P 500 by 40.676%.

Blueprint Medicines has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ardelyx offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Blueprint Medicines pays -- of its earnings as a dividend. Ardelyx pays out -- of its earnings as a dividend.

Blueprint Medicines quarterly revenues are $149.4M, which are larger than Ardelyx quarterly revenues of $74.1M. Blueprint Medicines's net income of $496K is higher than Ardelyx's net income of -$41.1M. Notably, Blueprint Medicines's price-to-earnings ratio is -- while Ardelyx's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Blueprint Medicines is 14.64x versus 2.37x for Ardelyx. Usually stocks with elevated PS ratios are considered overvalued.

Bristol-Myers Squibb has a net margin of 0.33% compared to Blueprint Medicines's net margin of 21.93%. Blueprint Medicines's return on equity of -49.13% beat Bristol-Myers Squibb's return on equity of 32.01%.

Blueprint Medicines has a consensus price target of $126.87, signalling downside risk potential of -1.19%. On the other hand Bristol-Myers Squibb has an analysts' consensus of $57.10 which suggests that it could grow by 21.69%. Given that Bristol-Myers Squibb has higher upside potential than Blueprint Medicines, analysts believe Bristol-Myers Squibb is more attractive than Blueprint Medicines.

Blueprint Medicines has a beta of 0.841, which suggesting that the stock is 15.895% less volatile than S&P 500. In comparison Bristol-Myers Squibb has a beta of 0.378, suggesting its less volatile than the S&P 500 by 62.23%.

Blueprint Medicines has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bristol-Myers Squibb offers a yield of 5.2% to investors and pays a quarterly dividend of $0.62 per share. Blueprint Medicines pays -- of its earnings as a dividend. Bristol-Myers Squibb pays out -54.35% of its earnings as a dividend.

Blueprint Medicines quarterly revenues are $149.4M, which are smaller than Bristol-Myers Squibb quarterly revenues of $11.2B. Blueprint Medicines's net income of $496K is lower than Bristol-Myers Squibb's net income of $2.5B. Notably, Blueprint Medicines's price-to-earnings ratio is -- while Bristol-Myers Squibb's PE ratio is 17.57x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Blueprint Medicines is 14.64x versus 2.00x for Bristol-Myers Squibb. Usually stocks with elevated PS ratios are considered overvalued.

AVITA Medical has a net margin of 0.33% compared to Blueprint Medicines's net margin of -74.86%. Blueprint Medicines's return on equity of -49.13% beat AVITA Medical's return on equity of -415.55%.

Blueprint Medicines has a consensus price target of $126.87, signalling downside risk potential of -1.19%. On the other hand AVITA Medical has an analysts' consensus of $16.95 which suggests that it could grow by 228.84%. Given that AVITA Medical has higher upside potential than Blueprint Medicines, analysts believe AVITA Medical is more attractive than Blueprint Medicines.

Blueprint Medicines has a beta of 0.841, which suggesting that the stock is 15.895% less volatile than S&P 500. In comparison AVITA Medical has a beta of 1.547, suggesting its more volatile than the S&P 500 by 54.653%.

Blueprint Medicines has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AVITA Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Blueprint Medicines pays -- of its earnings as a dividend. AVITA Medical pays out -- of its earnings as a dividend.

Blueprint Medicines quarterly revenues are $149.4M, which are larger than AVITA Medical quarterly revenues of $18.5M. Blueprint Medicines's net income of $496K is higher than AVITA Medical's net income of -$13.9M. Notably, Blueprint Medicines's price-to-earnings ratio is -- while AVITA Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Blueprint Medicines is 14.64x versus 1.87x for AVITA Medical. Usually stocks with elevated PS ratios are considered overvalued.

TG Therapeutics has a net margin of 0.33% compared to Blueprint Medicines's net margin of 4.19%. Blueprint Medicines's return on equity of -49.13% beat TG Therapeutics's return on equity of 19.78%.

Blueprint Medicines has a consensus price target of $126.87, signalling downside risk potential of -1.19%. On the other hand TG Therapeutics has an analysts' consensus of $41.20 which suggests that it could grow by 14.32%. Given that TG Therapeutics has higher upside potential than Blueprint Medicines, analysts believe TG Therapeutics is more attractive than Blueprint Medicines.

Blueprint Medicines has a beta of 0.841, which suggesting that the stock is 15.895% less volatile than S&P 500. In comparison TG Therapeutics has a beta of 1.937, suggesting its more volatile than the S&P 500 by 93.749%.

Blueprint Medicines has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TG Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Blueprint Medicines pays -- of its earnings as a dividend. TG Therapeutics pays out -- of its earnings as a dividend.

Blueprint Medicines quarterly revenues are $149.4M, which are larger than TG Therapeutics quarterly revenues of $120.9M. Blueprint Medicines's net income of $496K is lower than TG Therapeutics's net income of $5.1M. Notably, Blueprint Medicines's price-to-earnings ratio is -- while TG Therapeutics's PE ratio is 150.17x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Blueprint Medicines is 14.64x versus 15.00x for TG Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.